COMP <GO>
BRKR vs ABBV // FORWARD P/E MULTIPLE
Bruker Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BRKR 1
— ABBV 13
▲ FORWARD P/E MULTIPLE LEADER: BRKR
LAST: $62.00 (0.00%) • MKT CAP: $9.45B
forward-pe
22.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRKR VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRKR | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.90% | 70.20% | -24.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.30% | 29.00% | -27.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 75.7x | 33.3x | +42.40 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 0.46% | 3.47% | -3.01 | ABBV | /fcf-yield <GO> |
| Operating Margin | 2.00% | 24.60% | -22.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 6.90% | -7.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 2.10% | 8.60% | -6.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.24% | 2.27% | -2.03 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.81 | 5.33 | -2.52 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.2 | 65.1 | -8.90 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.15 | -0.18 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.0x | 113.1x | -91.10 | BRKR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.45B | $513.86B | -$504.41B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRKR REV | ABBV REV | BRKR GROSS % | ABBV GROSS % | BRKR FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.44B | $61.16B | 45.9% | 70.2% | $43.3M | $17.82B |
| FY 2024 | $3.37B | $56.33B | 49.0% | 70.0% | $136.0M | $17.83B |
| FY 2023 | $2.96B | $54.32B | — | — | $216.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRKR // BETA 0.97
ABBV // BETA 1.15